chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received vaccine past its 30-days expiry date vaccines went into 2-8 degree C thaw state on or about 24-Dec-2021; patient received vaccine past its 30 days expiry date; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient received vaccine past its 30 days expiry date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days expiry date vaccines went into 2-8 degree C thaw state on or about 24-Dec-2021) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Feb-2022 at 5:54 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 07-Feb-2022 at 5:54 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (patient received vaccine past its 30 days expiry date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received vaccine past its 30-days expiry date vaccines went into 2-8 degree C thaw state on or about 24-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient received vaccine past its 30 days expiry date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days expiry date vaccines went into 2-8 degree C thaw state on or about 24-Dec-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.   It was reported that, vaccine was administered on 07-Feb-2022 at 17:54:42.  No treatment details were reported.   This case was linked to MOD-2022-542869 (Patient Link).
Red rash at the injection site; Red / at the injection site; This case was reported by a nurse and described the occurrence of injection site rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix .5 ml. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site rash and injection site erythema. On an unknown date, the outcome of the injection site rash and injection site erythema were unknown.   It was unknown if the reporter considered the injection site rash and injection site erythema to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient developed a red rash at the injection site after a dose of Shingrix.
Physical exam appointment at 11AM. 11:50am phone call from mom. Just arrived home. Eyes swollen and bug-like bites on face and into hairline. No respiratory symptoms. 1 tsp. Dimetap at home. Seen back in office 12:20; 25mg Benadryl. No wheezing, hive- like rash. 1 PM: hives resolved.
8x9cm local reaction (brought in 3 days p/vax) occurring w/in 24hr on lt arm (lower deltoid area);
pain at site of injection immediately during and after injection  deltoid muscle soreness x1 week - gradually improving, but then developed soreness and stiffness of left shoulder joint with pain during lateral extension of left shoulder sensation and strength remained intact, was ultimately able to still full range of motion left arm, but had pain seen in office 1 week after injection, still having symptoms, but seemed to start to improve from day prior  no obvious joint swelling, non tender to deltoid muscle, no obvious deformity or abnormality no fever or warmth of the joint advised ibuprofen pen for pain and warm compresses and to continue to try and gently range of motion the shoulder
Medical Assistant was aware that lyophilized gEAntigen component needed to be mixed prior th shingrix injection.
pt recv vax 28NOV95 & on 31MAY97 pt exp chickenpox w/fever & numerous lesions;
pt recvd vax 16APR92, & expired 24APR92; ?SIDS;
This spontaneous report as received from a healthcare worker refers to a 15 year old patient of unknown gender. There was no information about the patient's concomitant medications and pertinent medical history reported. On 29-JUN-2015, the patient was vaccinated with an improperly stored dose of GARDASIL (lot# K023432, expiration date 18-JUN-2016) (strength, dose, route and site of administration were not provided). No adverse effects were reported. This is one of several reports from the same reporter. Additional information has been requested.
Freezer temperature never reached an acceptable range and was always warm by at least 2 degree C.; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Freezer temperature never reached an acceptable range and was always warm by at least 2 degree C.) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 029A21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Freezer temperature never reached an acceptable range and was always warm by at least 2 degree C.). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Freezer temperature never reached an acceptable range and was always warm by at least 2 degree C.) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  It was reported that there were 4 days temperature data (between 4/1/2022 and 4/4/2022) for the freezer storage unit, however it never reached an acceptable range and was always warm by at least 2 degree C. Between 2/22/21 to 4/26/22 there was no other temperature data available. Total 6640 doses of COVID-19 Moderna Vaccine were received by this facility during this time period and LOT numbers were provided (057M21A, 025L21B, 066H21A, 069H21A, 027H21B, 032F21A, 011F21A, 004F21A, 025C21A, 017C21A, 002C21A, 042B21A, 031B21A, 027B21A, 026B21A, 016B21A, 008B21A, 045A21A, 001B21A, 029A21A, 025A21A, 001A21A). Some vials might have been moved to a refrigerator at some point. There was no temperature data for that storage unit.  Treatment information was not reported.
the right arm pit is more swollen than the left arm pit. He says there are no bumps in the arm pit, just swelling./swollen and there is little bumps present.; Concerned about the inflammation; That evening he had pain in his arms; and body aches which today have resolved; This is a spontaneous report from a contactable consumer (patient) reported for himself for the 1st Dose administered.   A 40-years-old male patient received bnt162b2 (BNT162B2, Batch/Lot number was not reported), dose 1 via an unspecified route of administration, administered in Arm Right on 13Jun2021 as 1ST DOSE, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced the right arm pit is more swollen than the left arm pit and said there are no bumps in the arm pit, just swelling. swollen and there is little bumps present. (swelling on 15Jun2021 with outcome of not recovered , that evening he had pain in his arms on 13Jun2021 with outcome of recovered , and body aches which today have resolved on 13Jun2021 with outcome of recovered , concerned about the inflammation on 15Jun2021 with outcome of not recovered.
I started to feel chest pain toward the end of October, so possibly 2-3 weeks after the first dose. The pain was localized to the center of my chest, sort of on the left side of center. I went to the ER mid November 2021 because the pain was sharp. They took an x-ray and gave me a pain shot, nothing happened and they said I was fine. They did an EKG as well and said I was fine. I did a stress test two days ago and I found out that the cardiologist thinks I have ischemia in my heart. I am supposed to be getting a follow-up appointment. The pain in my chest hurts at rest and with activity. It's sharp and happens at random times every day.
Rash; Maternal exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) and RASH (Rash) in a 33-year-old female patient (gravida 3, para 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concurrent medical conditions included Supraventricular tachycardia and Chemical sensitivity (Sensitivity to metoprolol and distolic). Concomitant products included PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for Pregnancy, ACETYLSALICYLIC ACID (ASPIRIN 81), IRON and OMEPRAZOLE (PROTONIX [OMEPRAZOLE]) for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 29-Aug-2020 and the estimated date of delivery was 03-Jun-2021. On 12-Mar-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy). On 03-Apr-2021, the patient experienced RASH (Rash). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-seventh week of the pregnancy.  The patient was treated with HYDROCORTISONE for Rash, at an unspecified dose and frequency. On 12-Mar-2021, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved. At the time of the report, RASH (Rash) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Sep-2020, Pregnancy test: positive (Positive) Positive. On an unknown date, Prenatal screening test: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
High fever; Chills; Joint pain; Throwing up; Throat hurts; Injection site hurts and numb; Injection site hurts and numb; Headache that's not going away; Light headed; Nauseous; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm  on 07May2021 at 02:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient did not have any known allergies. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any concomitant medications within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 16Apr2021 at 02:30 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. On 07May2021 at 02:45, the patient experienced high fever, chills, joint pain, throwing up, throat hurt, injection site hurt and numb, headache that was not going away, light headed and nauseous. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/ department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events high fever, chills, joint pain, throwing up, throat hurt, injection site hurt and numb, headache that was not going away, light headed and nauseous was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sepsis with Acute hypoxic respiratory failure -2/2 COVID-19 PNA.  Currently on-on NC.  Titrate to keep sats 92-96% Remdesivir- yes
Narrative: Patient is a 61 yo male with PMG significant for HTN, HLD, sleep apnea, sleep disorder, and sleep disorder, and knee pain. Patient received 1st Pfizer COVID-19 vaccine dose on 3/2/21, and received 2nd dose 2 weeks later on 3/16/21. The team realized the 2nd dose was given too soon when they filled out his CDC card after the 2nd dose was given. Per the 3/17/21 MD note, "He was observed for 30 minutes and was asymptomatic. He was advised that there may be slight decreased efficacy of getting the second vaccine early and is unlikely to experience any adverse events from the scheduling error. He was advised to particularly pay attention in the news for booster doses related to new variants and will do so." On 3/29/21, reviewed on the vent w/ COVID-19 Vaccination Planning Team. Multiple failure points were identified: 1) The patient's COVID-19 vaccination appointments were scheduled 2 weeks apart (3/2/21 & 3/16/21) instead of 3 weeks apart (3/2/21 & 3/23/21); 2.) Upon 1st appointment check-in, staff didn't notice the 2nd dose was scheduled in 2 weeks; 3.) The patient's 3/2/21 1st Pfizer COVID-19 vaccine dose was not documented within system; 4.) Upon 2nd appointment check-in, check-in staff didn't notice the appointments were scheduled 2 weeks apart; and 5.) Nurse administering the 2nd vaccine did not notice there was no 1st dose note. The event was reviewed with staff involved and the following system-wide improvements were implemented: - Pfizer and Moderna COVID-19 vaccine calendar created to aid staff in identifying the 2nd appointment day; and - At the end of every clinic day, the clerk team provide a list of patients that checked in but haven't checked out, open encounters, and Action Required encounters. Staff must resolve the patient list that day. For Patient, COVID-19 vaccination notes were entered and his 2-dose series is listed in his immunization package. The vaccine clinic MD reviewed the event w/the patient at the time of identification and the 2nd dose did not need to be repeated per the CDC's Clinical Consideration for Use of COVID-19Vaccines Currently Authorized (Appendix A).
p/vax pt achy, bones & muscles (in back, across shoulders & middle) cramp, cold chills, nausea, T101-102;nothing to eat x 2 days;arm inj site very sore 7 warm to touch;advil did not completely relieve sx;will see PMD if sx are not better;
Had first Moderna Covid vaccine dose on 2/26.  Rash appeared on 3/15 on starting on her neck and spreading to her arms and shoulders; denies rash on her abdomen, torso, back, face and legs. Rash composed of maculopapular fixed lesions that are itchy; she did scratch and has secondary scabbing from inflicted skin damage. Itchiness worsened during warm shower. She took oral benadryl and OTC hydrocortisone which helped lessen the itchiness. She saw her PCP clinic 3/29 and was given a medrol dosepak; she took her first day yesterday and feels better-wants to stop.   Denies history of adverse reaction to injected medications/therapies/vaccines. No historical allergies, anaphylaxis.   At no time did she experience fevers, chills, conjunctivitis, congestion, shortness of breath, wheezing, swelling, urticaria, open lesions, blistering rash.
six months old was given the single vial presentation of Menveo; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 6-month-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number 27PE9, expiry date 31-DEC-2024) for prophylaxis.   On 13-NOV-2023, the patient received the 1st dose of Menveo. On 13-NOV-2023, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: six months old was given the single vial presentation of Menveo). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 13-NOV-2023 Nurse reported that a patient who was six months old was given the single vial presentation of Menveo for their first dose, which led to inappropriate age at vaccine. The reporter consented to follow up.
This spontaneous report as received from a pharmacist refers to a patient of 15 years old. The reporter reported that "client got the third dose of GARDASIL (lot# was unknown) too early. The third dose of GARDASIL (lot # was unknown) was administered 8 weeks after the second dose". No adverse effects reported. Additional information has been requested.
Rash developed to the medical area of left deltoid. Began this am area is the size of 1/2 dollar, warm to touch. Painful. No swelling. Will treat with BENADRYL and OMNICEF.
Vaccine given 4/30/08, on 5/3/08 rash started on neck spread to face on 5/4/08 red papules. On 5/5 hive rt side of abd. 5/6 vesicle on rt ear. On 5/5 started on Benadryl 50 mg HS. Prednison 20 mg PO QD x 4 days. Rash also itchy.  The patient was diagnosed by a dermatologist as having poison ivy.
Every few days, she gets sick with the same symptoms, which are nausea, fever, headache and chills; Every few days, she gets sick with the same symptoms, which are nausea, fever, headache and chills; Every few days, she gets sick with the same symptoms, which are nausea, fever, headache and chills; Every few days, she gets sick with the same symptoms, which are nausea, fever, headache and chills; This is a spontaneous report from a contactable consumer (Patient). A 20-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for Injection, Lot Number: EW0173) via an unspecified route of administration, administered in Arm Right on 05May2021 10:00 (At the age of 20-year-old) as dose 1, single for COVID-19 immunisation. The Patient's medical history was none. The patient's concomitant medications were not reported. Prior Vaccinations within 4 weeks was none. On 06May2021 the patient experienced every few days, she gets sick with the same symptoms, which are nausea, fever, headache and chills. The patient received the first dose of the covid vaccine, she has been sick three different times. This has reoccurred three times now. She was asking if it was normal to have reoccurring symptoms after the covid vaccine. The patient work was to get tested for covid. The patient second dose was scheduled for 28May2021. The patient underwent lab tests and procedures which included weight: 120 to 130 lbs. The outcome of the event were not recovered.  Follow-up attempts completed. No further information expected.
Fever 100.4, muscle aches, fatigue, headache, chills. Fatigue began morning after the vaccine. 17 hours after vaccine, fever, headache and chills began. All symptoms ended 36 hours after injection.
Dizziness & lightheadedness; Lightheadedness; This spontaneous case was reported by a pharmacist and describes the occurrence of DIZZINESS (Dizziness & lightheadedness) and DIZZINESS (Lightheadedness) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included MULTIVITAMINS [VITAMINS NOS] for an unknown indication.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Apr-2021, the patient experienced DIZZINESS (Dizziness & lightheadedness) and DIZZINESS (Lightheadedness). At the time of the report, DIZZINESS (Dizziness & lightheadedness) and DIZZINESS (Lightheadedness) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication taken by the patient include multivitamins.
After two weeks of the vaccination i had swollen lymph nodes and my neck was in pain a lot. I had to go to the doctors and check it out. I had to do further testing and the lymph nodes were increased and that's when they scheduled the ent check up. It went away after two weeks.
Pt recvd vax & exp constant shaking of head (side to side movements-cont); pt has EEG & MRI scheduled by neurologist;
pt recv vax 23JUL96 & 18SEP96  & 19SEP96 pt exp h/a & dizziness;sx were not treated;they persist as of 30SEP96;
10 days after first vaccine shot, a red, swollen area has appeared around injection site. The area itches and is painful to the touch. It is about 2 inches long and 1 inch wide.
Patient experienced "extreme pain" in arm, very red from armpit to 3 inches below elbow, Temp 100.4 for 2 days, Temp 99 by day 3. Passed out day after vaccination, reports weakness and unbalance which lasted 5 full days and slight redness remained at shot sight one week later.
Received HEPLISAV-B That Was Not Stored Properly; Initial Report Received on 11-Mar-2020  This report was received from the supervisor of a health center.  The reporter stated that on 10-Mar-2020 a 58-year-old female patient received HEPLISAV-B (lot # 933621) in the left deltoid.  The vaccine was reported to have not been stored properly and reached 48 degrees Fahrenheit for 13.5 hours.  The patient had not reported any adverse reactions at the time of report.  Company comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
BODY ACHES; FEVER; This spontaneous report received from a patient concerned a 41 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient had no known allergies. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 1808980 expiry: 20-JUN-2021) dose was not reported, administered on 02-APR-2021 to left arm for prophylactic vaccination. No concomitant medications were reported. On 02-APR-2021, the subject experienced body aches. On 02-APR-2021, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from body aches, and had not recovered from fever. This report was non-serious.
Pt received 4 vaccines on 8/1/12 Polio, TYPHIM Vi, J.E. (IXIARO), Rabies, (IMOVAX), pt reports that the next day (8/2/12) pt developed rash behind ear, ear itchy, spread to body, arms, & legs, slight improvement with CLARITIN - rash: macular & papular.
INJECTION SITE BECAME RED, SWOLLEN, INFLAMED AND HOT TO THE TOUCH. SHE SAID A KNOT CAME UP. SHE DID NOT REPORT TO US UNTIL 9/11 BUT SHE SAID IT IS MUCH BETTER.
Redness and burning 1500 Raised rash and fever and itching 1600 Itching scattered rash over 60% of body 1900
This spontaneous report as received from a certified medical assistant concerning a male patient of unknown age who on 23-MAY-2013 was vaccinated with an expired dose of VARIVAX (Merck), SQ, lot # 669845/0345AA, exp date 07-MAR-2013 (dose and site not provided). No adverse effect was reported. Additional information has been requested.
pt recvd vax;w/in 48 hrs,exp swollen throat,rash & an uneasy feeling;tx w/ dph;sx resolved in approx 48 hrs;